Madrigal Pharmaceuticals, INC Form 4 insider transactions

William John Sibold, President and CEO and a Director of Madrigal Pharmaceuticals, Inc., sold 2,500 shares of common stock on July 17, 2026.

Rebecca Taub, a Director at Madrigal Pharmaceuticals, was granted restricted stock units and stock options on June 17, 2026.

Richard S. Levy, a Director at Madrigal Pharmaceuticals, Inc., was granted restricted stock units and stock options on June 17, 2026.

Jacqualyn A. Fouse, a Director at Madrigal Pharmaceuticals, Inc., acquired 454 shares of common stock and was granted stock options for 766 shares.

Madrigal Pharmaceuticals Director James M. Daly was granted restricted stock units and stock options on June 17, 2026, as detailed in a Form 4 filing.

Madrigal Pharmaceuticals director Daniel J. Brennan was granted restricted stock units and a stock option, according to a Form 4 filing.

Baker Bros. Advisors LP and affiliated entities report grants of restricted stock units and non-qualified stock options to directors Julian C. Baker and Dr. Raymond Cheong.

Chief Medical Officer David Soergel sold 1,042 shares of Madrigal Pharmaceuticals common stock via a Rule 10b5-1 plan.

Director Richard S. Levy sold 5,282 shares of Madrigal Pharmaceuticals common stock via a Rule 10b5-1 trading plan.

Chief Medical Officer David Soergel sold 844 shares of Madrigal Pharmaceuticals to satisfy tax obligations related to RSU vesting.

Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, Inc., reported the grant of restricted stock units and stock options, alongside sales of common stock, including tax-related sales and those under a 10b5-1 plan.

Madrigal Pharmaceuticals CEO William John Sibold received new equity grants and sold shares to cover tax obligations.

Madrigal Pharmaceuticals' General Counsel, Shannon T. Kelley, increased her beneficial ownership through RSU and stock option grants, alongside a tax-related share sale.

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, received new equity grants and sold shares to cover tax obligations.

Madrigal Pharmaceuticals Director Rebecca Taub sold 491 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Madrigal Pharmaceuticals' Chief Medical Officer, David Soergel, received significant equity awards, including restricted stock units and stock options, aligning his interests with shareholders.

Mardi Dier, EVP and CFO of Madrigal Pharmaceuticals, sold 1,183 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Madrigal Pharmaceuticals Director Richard S. Levy exercised 2,500 stock options at $7.36 per share, increasing his direct common stock holdings.

Madrigal Pharmaceuticals director Richard S. Levy exercised 4,000 stock options at $16.46 per share, increasing his direct common stock holdings to 25,197 shares.

Madrigal Pharmaceuticals' Chief Commercial Officer, Carole Huntsman, sold shares totaling 910 units on January 26, 2026, for tax obligations and under a pre-arranged 10b5-1 trading plan.

Madrigal Pharmaceuticals' President and CEO, William John Sibold, sold 1,577 shares of common stock to cover tax withholding obligations related to restricted stock unit vesting.

Madrigal Pharmaceuticals Director Rebecca Taub sold 647 shares of common stock at $492.42 per share to cover tax withholding obligations related to restricted stock unit vesting.

Madrigal Pharmaceuticals' General Counsel, Shannon T. Kelley, reported two sales of common stock totaling 692 shares on January 20, 2026, including shares sold for tax withholding and under a 10b5-1 plan.

Madrigal Pharmaceuticals Director Rebecca Taub sold 2,238 shares of common stock at $490.77 each to cover tax withholding obligations from restricted stock unit vesting.

Madrigal Pharmaceuticals, Inc. granted 2,398 restricted stock units and options for 1,826 shares to Chief Accounting Officer Rita Thakkar, aligning executive incentives with long-term company performance.

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and subsequently sold 280 shares of common stock under a pre-arranged trading plan.

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and subsequently sold a corresponding number of common shares under a pre-arranged 10b5-1 trading plan.

Madrigal Pharmaceuticals Director Rebecca Taub exercised stock options and subsequently sold a portion of her common stock holdings under a pre-arranged trading plan.

Madrigal Pharmaceuticals director Rebecca Taub exercised stock options and subsequently sold 18,410 shares of common stock on January 9, 2026, pursuant to a pre-arranged trading plan.

Madrigal Pharmaceuticals Director Paul A. Friedman exercised stock options and subsequently sold 24,800 shares of common stock under a pre-arranged 10b5-1 trading plan.